ARCHIVES

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

Outcome Of Prostate Cancer Surgery Depends On Experience Of Surgeon

August 31, 2007

Funding Opportunities: Department of Defense Ovarian Cancer Research

May 5, 2000

Investigation finds no evidence FDA’s Crawford had affair with subordinate.

June 10, 2005

Patents: Myriad Patents Spectrometry To Assess DNA Polymorphisms

March 5, 1999

Tykerb Plus Herceptin Better Than Monotherapy, Study Says

December 25, 2009

House, Senate Reform Bills Move Closer To Floor Vote

August 12, 1994